Roivant Sciences vs Tscan Therapeutics
Tscan Therapeutics is the larger business, with $10.3m of revenue in fiscal 2025 against $8.3m for Roivant Sciences (1.3 times as much). Tscan Therapeutics grew faster (266.7% against -71.6%). Tscan Therapeutics kept more of each dollar of sales as profit: a net margin of -1256.8% against -3629.2%. Roivant Sciences carries less debt relative to equity (0.0% against 26.4%).
| Latest fiscal year | Roivant SciencesROIV, 2026 | Tscan TherapeuticsTCRX, 2025 |
|---|---|---|
| Revenue | $8.3m | $10.3m |
| Revenue growth | -71.6% | 266.7% |
| Net income | −$300m | −$130m |
| Operating margin | -6235.7% | -1315.4% |
| Net margin | -3629.2% | -1256.8% |
| Return on equity | -6.5% | -71.3% |
| Free cash flow | −$759m | −$140m |
| Cash | $1.42bn | $152m |
| Total debt | $0 | $32.5m |
| Debt to equity | 0.0% | 26.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 721 | 142 |
| Market value | $26.20bn | $24.4m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 1 buys, 117 sales | 3 buys, 0 sales |